Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Sponsor: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Summary
The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
Official title: Pilot Study of CD19 CAR-T Cells Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma in Children/Young Adults
Key Details
Gender
All
Age Range
1 Year - 30 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2020-10-26
Completion Date
2025-06
Last Updated
2024-08-28
Healthy Volunteers
No
Interventions
CD19 CAR-T-cells
One dose of CD19 CAR-T cells (1\*10e6 CAR+ T-cells/kg) by intravenous infusion.
Tocilizumab
Before 1h of CAR-T cells infusion a patient receive tocilizumab (8 mg/kg).
Locations (1)
Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
Minsk, Minsk Oblast, Belarus